While the majority of breast cancers are sensitive to the endocrine therapy, patients with triple-negative breast cancer (TNBC) exhibit poor outcomes as the subtype lacks effective therapeutic targets including ER, PR and human epidermal growth factor receptor 2 (HER2)/ErbB2. The gene discussed is ERBB2; the disease is breast carcinoma.